MBCOF (Marvel Biosciences) Cash Ratio: 0.17 (As of Apr. 2026) — 51% Below Median


MBCOF Marvel Biosciences Corp MBCOF
34 GF Score
Price $0.11
! 1 Warning Sign
View Full Analysis

What is Marvel Biosciences Cash Ratio?

Marvel Biosciences MBCOF -7.30% 34 Cash Ratio is 0.17 as of Apr. 2026, which is 51% below its 10-year median of 0.35. GuruFocus rates MBCOF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,385 Biotechnology companies, Marvel Biosciences ranks worse than 91.84% on this metric.

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Marvel Biosciences's Cash Ratio for the quarter that ended in Apr. 2026 was 0.17.

Marvel Biosciences has a Cash Ratio of 0.17. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Marvel Biosciences's Cash Ratio or its related term are showing as below:

MBCOF' s Cash Ratio Range Over the Past 10 Years
Min: 0.03   Med: 0.35   Max: 21.37
Current: 0.17

During the past 6 years, Marvel Biosciences's highest Cash Ratio was 21.37. The lowest was 0.03. And the median was 0.35.

MBCOF's Cash Ratio is ranked worse than
91.84% of 1385 companies
in the Biotechnology industry
Industry Median: 2.95 vs MBCOF: 0.17

Marvel Biosciences  (OTCPK:MBCOF) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Marvel Biosciences Cash Ratio Related Terms


Marvel Biosciences Cash Ratio Historical Data

* Premium members only.

The historical data trend for Marvel Biosciences's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences Cash Ratio Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cash Ratio
Get a 7-Day Free Trial 21.46 0.83 0.40 0.10 0.03

Marvel Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.03 0.15 0.07 0.17

MBCOF vs VRTX, REGN, ALNY: Cash Ratio Comparison

For the Biotechnology subindustry, Marvel Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences Cash Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Cash Ratio falls into.


MBCOF
34GF Score
Marvel Biosciences Corp MBCOF
Cash Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marvel Biosciences Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Marvel Biosciences's Cash Ratio for the fiscal year that ended in Jul. 2025 is calculated as:

Cash Ratio (A: Jul. 2025 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.094/3.165
=0.03

Marvel Biosciences's Cash Ratio for the quarter that ended in Apr. 2026 is calculated as:

Cash Ratio (Q: Apr. 2026 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.316/1.877
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Ratio →
What does a Cash Ratio of 0.17 mean?
Marvel Biosciences (MBCOF) has a Cash Ratio of 0.17 as of Apr. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Marvel Biosciences and its competitors. This is 51% below median its historical median of 0.35. Over the past decade, Marvel Biosciences' Cash Ratio has ranged from 0.03 to 21.37. According to the industry distribution chart, Marvel Biosciences ranks #1272 out of 1385 companies in the Biotechnology industry, placing it in the top 91.8%.
Is Marvel Biosciences' Cash Ratio too high?
Marvel Biosciences' current Cash Ratio of 0.17 is 51% below median its 10-year median of 0.35. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 21.37. The Biotechnology industry median Cash Ratio is 2.95. Marvel Biosciences' value of 0.17 is 94.2% below this industry median. Based on the distribution chart, Marvel Biosciences ranks #1272 out of 1385 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marvel Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marvel Biosciences ranks #1272 out of 1385 companies for Cash Ratio. This places Marvel Biosciences in the lower half of its industry. The industry median Cash Ratio is 2.95. Marvel Biosciences' value of 0.17 is 94.2% below this benchmark. Historically, Marvel Biosciences' own Cash Ratio has ranged from 0.03 to 21.37 over the past decade. While the company's 10-year median is 0.35 vs. the industry median of 2.95, Marvel Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marvel Biosciences's current Cash Ratio of 0.17 is 94.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Marvel Biosciences and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marvel Biosciences's current Cash Ratio is 0.17, which is 51% below median its own 10-year median of 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current Cash Ratio of 0.17. The current Cash Ratio is 0.17, which is 51% below median its 10-year median of 0.35 and 94.2% below the Biotechnology industry median of 2.95. Marvel Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current Cash Ratio is 0.17 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marvel Biosciences Business Description

Other Exchanges MRVL:Canada
Address 505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
34GF Score

Get the complete analysis for MBCOF

Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price